Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2008-08-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Niacin Therapy on Lipoprotein Composition and Function
NCT02322203
Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
NCT01250990
Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)
NCT00298909
Short-term Effect of Extended-release Niacin on Endothelial Function.
NCT01942291
The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)
NCT00346970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Niacin
Niacin
1000 mg tablets once per day
Placebo
Active Placebo
100 mg Niacin tablets once per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Niacin
1000 mg tablets once per day
Active Placebo
100 mg Niacin tablets once per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HDL-cholesterol \<50 for men and \<55 for women
* If taking a statin, stable dose for past one month
* Glucose \<200 mg/dL and HbA1c \<9%
* Transplant recipients who are in stage 2-3 CKD; 1-year post transplant; and have had no rejection episodes in the 6-months prior to study entry
Exclusion Criteria
* Any of the following conditions:
* uncontrolled peptic ulcer disease
* active liver disease OR abnormal SGOT/SGPT
* history of adverse reaction to niacin
* contra-indication to aspirin
* concurrent fibrate therapy
* history of gout
* serum phosphorus levels below 2.7mg/dl
* Nursing
* Pregnancy
21 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Tufts Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Sarnak, MD
Role: PRINCIPAL_INVESTIGATOR
Tufts Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tufts Medical Center
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.